endostatin-LDP C-terminal fusion protein

C-terminal fusion of Lidamycin apoprotein (LDP) to Endostatin (ES) . This fusion protein displays anti-angiogenic, anti-metastatic and anti-oncogenic properties in human lung tumor samples

Also Known As:

Networked: 1 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Fu, Yan: 1 article (10/2013)
2.	Jiang, Wen-guo: 1 article (10/2013)
3.	Li, Liang: 1 article (10/2013)
4.	Li, Yi: 1 article (10/2013)
5.	Lu, Xin-an: 1 article (10/2013)
6.	Luo, Yongzhang: 1 article (10/2013)
7.	Shang, Bo-yang: 1 article (10/2013)
8.	Zhang, Sheng-hua: 1 article (10/2013)
9.	Zhen, Yong-su: 1 article (10/2013)
10.	Zhou, Daifu: 1 article (10/2013)

Related Diseases

1.	Carcinoma (Carcinomatosis) 10/15/2013 - "ES-LDP and ES show higher binding capability than LDP to lung carcinoma; in addition, ES-LDP and ES share similar binding capability. " 10/15/2013 - "Furthermore, the enediyne-energized fusion protein ES-LDP-AE demonstrated significant efficacy against lung carcinoma xenograft in athymic mice. "
2.	Neoplasms (Cancer) 10/15/2013 - "Evidently, ES-LDP accumulated in the tumor and suppressed tumor growth and metastasis. " 10/15/2013 - "Tissue microarray was used to analyze the binding affinity of LDP, ES or ES-LDP with specimens of human lung tissue and lung tumor. "
3.	Neoplasm Metastasis (Metastasis) 10/15/2013 - "Evidently, ES-LDP accumulated in the tumor and suppressed tumor growth and metastasis. "

Related Drugs and Biologics

1.	Proteins (Proteins, Gene)
2.	LDP-endostatin N-terminal fusion protein